MaxCyte, Inc. Total Voting Rights (7231G)
01 June 2017 - 1:30AM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 7231G
MaxCyte, Inc.
31 May 2017
MaxCyte, Inc.
("MaxCyte" or the "Company")
Total Voting Rights
Maryland, USA -31 May 2017: MaxCyte (LSE: MXCT, MXCR) announces
that, following an exercise of options, 22,435 new shares of common
stock of $0.01 each in the Company (the "Common Stock") were issued
from the blocklisting facility granted 5 May 2017.
The total issued stock capital of the Company has consequently
increased to 50,836,962 Common Stock. There is no Common Stock held
in treasury. Therefore, the total number of voting rights in the
Company is 50,836,962. Stockholders in the Company may use this
figure as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the capital of the Company.
The number of unrestricted shares of Common Stock trading under
the symbol 'MXCT' is 43,561,962 and the number of restricted shares
of Common Stock trading under the symbol 'MXCR' is 7,275,000. The
number of Common Stock capable of being issued under the
blocklisting facility is 977,565 Common Stock.
- ENDS -
For further information please contact:
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Fabien Holler
Duncan Monteith
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
About MaxCyte
MaxCyte (LSE: MXCT), is a US-based global company dedicated to
driving the acceleration of the discovery, development,
manufacturing and commercialisation of next-generation, cell-based
medicines. The Company provides its patented, high-performance cell
engineering platform to biopharmaceutical partners engaged in drug
discovery and development, biomanufacturing, and cell therapy,
including gene editing and immuno-oncology. With its robust
delivery platform, MaxCyte's team of scientific experts helps its
partners to unlock their product potential and solve problems. This
platform allows for the engineering of nearly all cell types,
including human primary cells, with any molecule, at any scale. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large-scale, clinical and
commercial grade cell engineering in a non-viral system and with
low-toxicity concerns. The Company's cell-engineering platform is
FDA-accredited, providing MaxCyte's customers and partners with an
established regulatory path to commercialise cell-based
medicines.
For more information, visit http://www.maxcyte.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVROKDDPBBKDFPN
(END) Dow Jones Newswires
May 31, 2017 11:30 ET (15:30 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024